Teva Pharmaceutical Industries Ltd. and Polpharma Biologics have entered a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab). This medication treats multiple sclerosis, a chronic disease of the central nervous system.
Teva holds exclusive rights to commercialize the biosimilar in major global markets pending regulatory approval. The agreement covers both intravenous and subcutaneous versions of the drug. Polpharma Biologics will manage all development and manufacturing responsibilities.
The deal advances Teva’s "Pivot to Growth" strategy by expanding its biosimilar drug portfolio. This partnership follows several recent positive developments within Teva’s biosimilar programs. The collaboration aims to improve patient access to biologic medicines for multiple sclerosis.